organization · Reporting owner
PDL BIOPHARMA, INC.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evofem Biosciences, Inc.
Report date May 21, 2020 · Filed May 26, 2020
Section 16 reporting ended · disclosed 2020-05-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-21 transaction · row 1
1 source rowRow 1 · 2020-05-21 · Other · Disposed 13,333,334 · Balance 0 F1: Represents a pro rata distribution in-kind of the shares formerly held by the Reporting Person to its stockholders for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution in-kind of the shares formerly held by the Reporting Person to its stockholders for no consideration.
LENSAR, Inc.
Report date September 29, 2020 · Filed October 01, 2020
Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-09-29 · Purchase · Acquired 8,703 · Balance 8,667,397 Row 2 · 2020-10-01 · Other · Disposed 8,667,397 · Balance 0 F1: In connection with the separation of the Issuer from the Reporting Person on October 1, 2020, the Reporting Person distributed all of the shares of common stock of the Issuer in the form of a dividend to its stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the separation of the Issuer from the Reporting Person on October 1, 2020, the Reporting Person distributed all of the shares of common stock of the Issuer in the form of a dividend to its stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 1, 2020 21:52 UTC | LENSAR, Inc. LNSR · Entity 6733 | OtherCommon Stock | 8,667,397 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026691 · doc4.xml · nonDerivative · entry 2 PDL BIOPHARMA, INC. · CIK 0000882104 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the separation of the Issuer from the Reporting Person on October 1, 2020, the Reporting Person distributed all of the shares of common stock of the Issuer in the form of a dividend to its stockholders. F1 · shares: In connection with the separation of the Issuer from the Reporting Person on October 1, 2020, the Reporting Person distributed all of the shares of common stock of the Issuer in the form of a dividend to its stockholders. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 21:52 UTC | LENSAR, Inc. LNSR · Entity 6733 | PurchaseCommon Stock | 8,703 | $11.16 | $97,125.48 |
DisclosureSEC source: 0000899243-20-026691 · doc4.xml · nonDerivative · entry 1 PDL BIOPHARMA, INC. · CIK 0000882104 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,667,397 Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:43 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | OtherCommon Stock | 13,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014185 · doc4.xml · nonDerivative · entry 1 PDL BIOPHARMA, INC. · CIK 0000882104 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents a pro rata distribution in-kind of the shares formerly held by the Reporting Person to its stockholders for no consideration. Read SEC document |
| June 10, 2019 Filed Jun 10, 2019 22:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantWarrants (Right to Buy) · Derivative | 1,666,667 | Not disclosed Strike: $6.38 | Not disclosed |
DisclosureSEC source: 0000899243-19-016240 · doc4.xml · derivative · entry 2 PDL BIOPHARMA, INC. · CIK 0000882104 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666,667 Underlying: Common Stock · 1,666,667 shares Expires 2026-06-10 F1 · price: Pursuant to that certain Securities Purchase Agreement, dated as of April 10, 2019, by and among the Issuer, the Reporting Person and the other parties thereto, on June 10, 2019, the Reporting Person purchased 6,666,667 shares of Common Stock of the Issuer, at a price of $4.50 per share, and received warrants to purchase up to an additional 1,666,667 shares of Common Stock for an aggregate purchase price of approximately $30.0 million. Read SEC document |
| June 10, 2019 Filed Jun 10, 2019 22:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 6,666,667 | $4.50 | $30,000,001.50 |
DisclosureSEC source: 0000899243-19-016240 · doc4.xml · nonDerivative · entry 1 PDL BIOPHARMA, INC. · CIK 0000882104 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333,334 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.